Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupLTS:0A05 +2.49%89 PB Ratio is 6.53 as of Jul. 17, 2026, which is 25% below its 10-year median of 8.67. GuruFocus rates LTS:0A05 with a GF Score™ of 89/100 and a GF Value™ of CHF168.11 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Medacta Group ranks worse than 85.01% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-17), Medacta Group's share price is CHF139.80. Medacta Group's Book Value per Share for the quarter that ended in Dec. 2025 was CHF21.40. Hence, Medacta Group's PB Ratio of today is 6.53.
Good Sign:
Medacta Group SA stock PB Ratio (=6.54) is close to 10-year low of 6.19.
The historical rank and industry rank for Medacta Group's PB Ratio or its related term are showing as below:
LTS:0A05'
s PB Ratio Range Over the Past 10 Years
Min: 6.19 Med: 8.67 Max: 19.57
Current: 6.56
During the past 11 years, Medacta Group's highest PB Ratio was 19.57. The lowest was 6.19. And the median was 8.67.
LTS:0A05's PB Ratio is ranked worse than 85.01% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs LTS:0A05: 6.56
During the past 12 months, Medacta Group's average Book Value Per Share Growth Rate was 20.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 17.90% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Medacta Group was 32.90% per year. The lowest was -5.20% per year. And the median was 16.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Medacta Group PB Ratio Related Terms
Medacta Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Medacta Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medacta Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Medacta Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Medacta Group's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Medacta Group (LTS:0A05) has a PB Ratio of 6.53 as of Jul. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medacta Group and its competitors. This is 25% below median its historical median of 8.67. Over the past decade, Medacta Group's PB Ratio has ranged from 6.19 to 19.57. According to the industry distribution chart, Medacta Group ranks #669 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 85%.
Is Medacta Group's PB Ratio too high?
Medacta Group's current PB Ratio of 6.53 is 25% below median its 10-year median of 8.67. Over the past 10 years, this metric has ranged from a low of 6.19 to a high of 19.57. The Medical Devices & Instruments industry median PB Ratio is 2.05. Medacta Group's value of 6.53 is 218.5% above this industry median. Based on the distribution chart, Medacta Group ranks #669 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medacta Group has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #669 out of 787 companies for PB Ratio. This places Medacta Group in the lower half of its industry. The industry median PB Ratio is 2.05. Medacta Group's value of 6.53 is 218.5% above this benchmark. Historically, Medacta Group's own PB Ratio has ranged from 6.19 to 19.57 over the past decade. While the company's 10-year median is 8.67 vs. the industry median of 2.05, Medacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current PB Ratio of 6.53 is 218.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medacta Group and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current PB Ratio is 6.53, which is 25% below median its own 10-year median of 8.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (LTS:0A05) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF168.11, compared to a current price of CHF139.80 — trading 16.8% below its estimated fair value. The current PB Ratio is 6.53, which is 25% below median its 10-year median of 8.67 and 218.5% above the Medical Devices & Instruments industry median of 2.05. Medacta Group's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Medacta Group (LTS:0A05), the current PB Ratio is 6.53 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (LTS:0A05) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of CHF139.80 is trading 16.8% below its estimated GF Value™ of CHF168.11.
GuruFocus considers Medacta Group to be Modestly Undervalued.
Key valuation signals for LTS:0A05:
PB Ratio: 6.53 (25% below median its 10-year median of 8.67)
GF Value™: CHF168.11 vs. price of CHF139.80 (16.8% below fair value)
Industry Position: 218.5% above the Medical Devices & Instruments median (#669 of 787)
No single metric tells the full story. See the LTS:0A05 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
89GF Score
Get the complete analysis for LTS:0A05
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0A05 has been successfully added to your 
